Electrophysiological evaluation and 18-month follow-up of two regimens with aflibercept for neovascular age-related macular degeneration
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-2622
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Electrophysiological evaluation and 18-month follow-up of two regimens with aflibercept for neovascular age-related macular degeneration ; volume:144 ; number:2 ; day:26 ; month:2 ; year:2022 ; pages:99-115 ; date:4.2022
Documenta ophthalmologica ; 144, Heft 2 (26.2.2022), 99-115, 4.2022
- Creator
-
Schroeder, Marion
Kjellström, Ulrika
Lövestam-Adrian, Monica
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s10633-021-09863-7
- URN
-
urn:nbn:de:101:1-2022070521515041927983
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:31 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Schroeder, Marion
- Kjellström, Ulrika
- Lövestam-Adrian, Monica
- SpringerLink (Online service)
Other Objects (12)
Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
Impact of intravitreal aflibercept dosing regimens in treatment-naïve patients with neovascular age-related macular degeneration: 2-year results of RAINBOW
Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study
Retinal vasculitis after intravitreal aflibercept 8 mg for neovascular age-related macular degeneration
Short-term choroidal vascular changes after aflibercept therapy for neovascular age-related macular degeneration
Treatment regimens for optimising outcomes in patients with neovascular age-related macular degeneration
Three-year outcome of aflibercept treatment for Japanese patients with neovascular age-related macular degeneration
Four-Year Outcome of Aflibercept for Neovascular Age-Related Macular Degeneration and polypoidal choroidal vasculopathy
Treat-and-Extend Versus Pro re nata Regimens of Ranibizumab and Aflibercept in Neovascular Age-Related Macular Degeneration: A Comparative Study from Routine Clinical Practice
Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration
Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
Double-dose investigation of aflibercept in neovascular age-related macular degeneration (DIANA): a real-world study
Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
Impact of intravitreal aflibercept dosing regimens in treatment-naïve patients with neovascular age-related macular degeneration: 2-year results of RAINBOW
Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study
Retinal vasculitis after intravitreal aflibercept 8 mg for neovascular age-related macular degeneration
Short-term choroidal vascular changes after aflibercept therapy for neovascular age-related macular degeneration
Treatment regimens for optimising outcomes in patients with neovascular age-related macular degeneration
Three-year outcome of aflibercept treatment for Japanese patients with neovascular age-related macular degeneration
Four-Year Outcome of Aflibercept for Neovascular Age-Related Macular Degeneration and polypoidal choroidal vasculopathy
Treat-and-Extend Versus Pro re nata Regimens of Ranibizumab and Aflibercept in Neovascular Age-Related Macular Degeneration: A Comparative Study from Routine Clinical Practice
Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration
Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
Double-dose investigation of aflibercept in neovascular age-related macular degeneration (DIANA): a real-world study
Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
Impact of intravitreal aflibercept dosing regimens in treatment-naïve patients with neovascular age-related macular degeneration: 2-year results of RAINBOW
Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study
Retinal vasculitis after intravitreal aflibercept 8 mg for neovascular age-related macular degeneration
Short-term choroidal vascular changes after aflibercept therapy for neovascular age-related macular degeneration
Treatment regimens for optimising outcomes in patients with neovascular age-related macular degeneration
Three-year outcome of aflibercept treatment for Japanese patients with neovascular age-related macular degeneration
Four-Year Outcome of Aflibercept for Neovascular Age-Related Macular Degeneration and polypoidal choroidal vasculopathy
Treat-and-Extend Versus Pro re nata Regimens of Ranibizumab and Aflibercept in Neovascular Age-Related Macular Degeneration: A Comparative Study from Routine Clinical Practice
Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration
Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration